Navigation Links
Study uncovers placental microtransfusions lead to transmission of AIDS virus during childbirth

Transmission of HIV, the virus that causes AIDS, from pregnant women to their infants sometime during childbirth is a huge international problem, studies have shown. Between 25 percent and 35 percent of babies born to untreated HIV-infected mothers become infected themselves.

That's a half million newborn worldwide every year facing chronic illness and premature death on their first day out of the safety of the womb.

"The question has always been how does the virus get from the mothers to the babies?" said principal investigator Dr. Steven Meshnick, professor of epidemiology at the University of North Carolina at Chapel Hill School of Public Health. "We have known very little about it."

Now, Meshnick and colleagues think they have discovered a major reason why that occurs. A new study they conducted with 149 pregnant HIV-infected women in the African nation of Malawi showed that tiny amounts of virus-laden blood leak from women's placentas to babies during labor. All of the subjects and their babies had been given single-dose anti-retroviral drugs to minimize HIV transmission.

"This work shows strongly for the first time that what we call placental microtransfusions during birth are responsible for a large part of the transmission of HIV from mother to baby," the scientist said. "To our knowledge, there have never been any data like this before."

A report on the research appears today (Nov. 21) in the latest issue of the journal PloS Medicine. PloS is an acronym for Public Library of Science.

Besides Meshnick, UNC epidemiology authors are Dr. Jesse Kwiek, a postdoctoral fellow; graduate student Alisa Alker; and assistant professor Dr. William Miller, also assistant professor of medicine at the UNC School of Medicine. Other authors are Drs. Victor Mwapasa, Eyob Tadesse and Malcolm Molyneux of the University of Malawi, Dr. Danny A. Milner, a Harvard University pathologist, and Dr. Stephen Rogerson, associate professor of medicine at the University of Melbourne.

The study involved measuring -- in umbilical cord blood samples -- a protein known as placental alkaline phosphatase as an indicator of maternal-fetal microtransfusion.

"This enzyme, made in the placenta, is very big -- usually too big to pass through the natural barrier that protects babies from disease-causing organisms mothers sometimes carry before birth," Meshnick said. "We figured that if we found it in blood from the umbilical cord, which links the placenta to the baby, that would be an indication of mixing, that something tore in the placenta and leaked the mothers' virus-contaminated blood to the infant."

Researchers then compared what they found in cord blood to whether or not infants were infected with HIV, he said.

"We looked for a statistical relationship between the presence of the enzyme and the risk of infection in the babies," Meshnick said. "We found a very strong correlation between the enzyme and the risk of infection."

It appears that transmission of the virus occurs during labor -- when contractions occur -- rather than during passage of the baby through the birth canal, he said.

"It has been known for a long time that HIV-infected women who undergo caesarean section before they go into labor do not transmit the virus, whereas those who undergo emergency C-sections after they go into labor do transmit it," Meshnick said. "What we saw was consistent with this. It looks like direct mother-to-child blood mixing occurring during labor leads to infection."

The new findings indicate that intervening just before birth by such suggested methods as sanitizing the birth canal may not work, he said. A better alternative might be to have pregnant women start taking anti-retrovirals before going into labor.


'"/>

Source:University of North Carolina at Chapel Hill


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology: